ArticleCardiology journal2025
Prognostic role of the serum uric acid-to-serum creatinine ratio in patients with st-elevation myocardial infarction and multivessel coronary artery disease.
Article in Cardiology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum uric acid-to-creatinine ratio as a predictor for the severity of coronary artery lesions.BMC research notes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to investigate whether serum uric acid to serum creatinine ratio (SUA/SCr) predicts the early major adverse cardiovascular and cerebrovascular events (MACCEs) in patients with ST elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVCAD).
methodsThis study was designed retrospectively and included 572 patients with a mean age of 61.9 ± 12.3 years who presented with STEMI and had MVCAD. The patients were divided into 2 groups as those with and without MACCEs, taking into account the 30-day follow-up period. Serum uric acid, and serum creatinine were obtained at admission. The SUA/SCr of all patients were calculated and evaluated the relationship of SUA/SCr with the 30-day MACCEs.
resultsDuring the mean 27.0 ± 7.7 day follow-up period, 58 (10.1%) patients died, and 84 patients (14.7%) suffered MACCEs. According to multivariable cox regression analysis, advanced age (HR: 1.020, p = 0.028), smoking (HR: 2.513, p = 0.001), lower left ventricular ejection fraction (HR: 0.962, p = 0.001), TIMI < 3 flow (HR: 0.425, p < 0.001), higher syntax score (HR: 1.067, p < 0.001), and higher SUA/SCr (HR: 1.1029, p = 0.011) independently predicted the 30-day MACCEs. The area under the curve for SUA/SCr was 0.606 with a p value of 0.002. The Kaplan Meier curves represented that high-risk patients with SUA/SCr greater than 4.58 had significantly higher MACCEs than low-risk group during the follow up period after index hospitalization (p = 0.001).
conclusionsNewly defined promising oxidative and inflammatory biomarker, SUA/SCr can be a potential predictor of MACCEs within 30 days and decision-making treatment in STEMI and MVCAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.